Genetic Signatures (ASX:GSS) Operating Margin %: -101.88% (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Genetic Signatures Operating Margin %?

Genetic Signatures ASX:GSS -1.49% Operating Margin % is -101.88% as of Dec. 2025. The stock has 4 warning signs investors should review. Among 203 Medical Diagnostics & Research companies, Genetic Signatures ranks worse than 81.77% on this metric.

Operating Margin % is calculated as Operating Income divided by its Revenue. Genetic Signatures's Operating Income for the six months ended in Dec. 2025 was A$-8.84 Mil. Genetic Signatures's Revenue for the six months ended in Dec. 2025 was A$8.68 Mil. Therefore, Genetic Signatures's Operating Margin % for the quarter that ended in Dec. 2025 was -101.88%.

The historical rank and industry rank for Genetic Signatures's Operating Margin % or its related term are showing as below:

ASX:GSS' s Operating Margin % Range Over the Past 10 Years
Min: -249.75   Med: -117.28   Max: 8.09
Current: -112.54


ASX:GSS's Operating Margin % is ranked worse than
81.77% of 203 companies
in the Medical Diagnostics & Research industry
Industry Median: -3.35 vs ASX:GSS: -112.54

Genetic Signatures's 5-Year Average Operating Margin % Growth Rate was 0.00% per year.

Genetic Signatures's Operating Income for the six months ended in Dec. 2025 was A$-8.84 Mil. Its Operating Income for the trailing twelve months (TTM) ended in Dec. 2025 was A$-18.10 Mil.


Genetic Signatures  (ASX:GSS) Operating Margin % Explanation

Just like Gross Margin %, it is important to see a company maintains its operating margin over time. Among the same industry, a company with higher operating margin is more efficient in its operation. It is also more stable during industry slowdown or recessions. Peter Lynch prefers those with higher margins than those with lower margins.


Be Aware

Operating Margin % can be manipulated by adjusting the rate of depreciation, depletion and amortization (DDA).

If a company is facing competition, its Operating Margin % may decline. Often the Operating Margin % declines well before the company's Revenue or even profit decline. Therefore, Operating Margin % is a very important indicator of whether the company is facing problems.

For instance, by 2012, Nokia (NOK)'s problems were well known and its stock had lost more than 90% of its market value since 2007. But Nokia’s Operating Margin % had already been in decline since 2002, although its Earnings per Share (Diluted) were still rising. Investors who paid attention to Operating Margin % would have avoided this huge loss. The same can be said for Research-in-Motion (RIMM).

Therefore, Operating Margin % is a very important screening filter for GuruFocus. GuruFocus's Buffett-Munger screener requires that the profit margin is either consistent or expanding. The Model Portfolio of the Buffett-Munger screener has outperformed the market every year since inception in 2009.


Genetic Signatures Operating Margin % Related Terms


Genetic Signatures Operating Margin % Historical Data

* Premium members only.

The historical data trend for Genetic Signatures's Operating Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Genetic Signatures Operating Margin % Chart

Genetic Signatures Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
Operating Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 4.80 8.09 -69.04 -228.68 -116.23

Genetic Signatures Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Operating Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -335.77 -166.05 -108.57 -125.04 -101.88

ASX:GSS vs TMO, DHR, IDXX: Operating Margin % Comparison

For the Diagnostics & Research subindustry, Genetic Signatures's Operating Margin %, along with its competitors' market caps and Operating Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Genetic Signatures Operating Margin % vs Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Genetic Signatures's Operating Margin % distribution charts can be found below:

* The bar in red indicates where Genetic Signatures's Operating Margin % falls into.



Genetic Signatures Operating Margin % Calculation

Operating Margin % - also known as operating income margin, operating profit margin and return on sales (ROS) - is the ratio of Operating Income divided by net sales or Revenue, usually presented in percent.

Genetic Signatures's Operating Margin % for the fiscal year that ended in Jun. 2025 is calculated as

Operating Margin %=Operating Income (A: Jun. 2025 ) / Revenue (A: Jun. 2025 )
=-18.481 / 15.9
=-116.23 %

Genetic Signatures's Operating Margin % for the quarter that ended in Dec. 2025 is calculated as

Operating Margin %=Operating Income (Q: Dec. 2025 ) / Revenue (Q: Dec. 2025 )
=-8.844 / 8.681
=-101.88 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Operating Margin % →
What does a Operating Margin % of -101.88% mean?
Genetic Signatures (ASX:GSS) has a Operating Margin % of -101.88% as of Dec. 2025. Operating margin is the ratio of total operating income to net sales. View historical data on Genetic Signatures and its competitors. According to the industry distribution chart, Genetic Signatures ranks #166 out of 203 companies in the Medical Diagnostics & Research industry, placing it in the top 81.8%.
Is Genetic Signatures' Operating Margin % too high?
Genetic Signatures' current Operating Margin % is -101.88%. Based on the distribution chart, Genetic Signatures ranks #166 out of 203 companies in the Medical Diagnostics & Research industry, which is in the bottom quartile relative to peers.
How does Genetic Signatures' Operating Margin % compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Genetic Signatures ranks #166 out of 203 companies for Operating Margin %. This places Genetic Signatures in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Operating Margin % for a Medical Diagnostics & Research company?
A good Operating Margin % depends on the Medical Diagnostics & Research industry context. However, Operating Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Operating Margin % mean?
A high Operating Margin % can signal that a stock is expensive relative to its fundamentals. Operating margin is the ratio of total operating income to net sales. View historical data on Genetic Signatures and its competitors. Genetic Signatures's current Operating Margin % is -101.88%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Genetic Signatures stock overvalued right now?
Based on GuruFocus' analysis, Genetic Signatures (ASX:GSS) is currently considered Possible Value Trap. The stock's GF Value™ is A$0.38, compared to a current price of A$0.07 — trading 82.6% below its estimated fair value. The current Operating Margin % is -101.88%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Operating Margin % calculated?
Operating Margin % is calculated from a company's financial statements. For Genetic Signatures (ASX:GSS), the current Operating Margin % is -101.88% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Genetic Signatures Business Description

Address 7 Eliza Street, Newtown, Sydney, NSW, AUS, 2042
Genetic Signatures Ltd is a specialist molecular diagnostics company, specializing in syndromic multiplex real-time PCR testing. The company offers products for the routine detection of infectious diseases and pathogens. It has three operating segments based on regions: Asia Pacific, EMEA, and Americas. It generates the majority of its revenue from the Asia Pacific region. The group's operations are based in Australia, with sales and support teams in the UK, Germany, and the United States.